Jennison Associates LLC recently announced the acquisition of new stake in Constellium SE (NYSE:CSTM). The institutional investor has increased its shareholding in the Basic Materials company by 2.46% to 5.68 million shares with purchase of 0.14 million shares. This fresh investment now brings its stake to 3.94% valued currently at $98.81 million. In addition, Oberweis Asset Management, Inc. raised its holdings by 0.13 million to 2.93 million shares. And Lancaster Investment Management L has lifted its position by 7.14% or 0.17 million shares – to 2.6 million shares.
With over 0.5 million Constellium SE (CSTM) shares trading Friday and a closing price of $19.96 on the day, the dollar volume was approximately $9.92 million. The shares have shown a positive half year performance of 16.05% and its price on 12/29/23 lost nearly -2.11%. Currently, there are 144.30M common shares owned by the public and among those 125.30M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The top 3 mutual fund holders in Constellium SE are Janus Henderson Contrarian Fund, T Rowe Price Small Cap Value Fund, and Fidelity Value Fund. Janus Henderson Contrarian Fund owns 7.9 million shares of the company’s stock, all valued at over $137.53 million. The company sold -0.24 million shares recently to bring their total holdings to about 5.48% of the shares outstanding. T Rowe Price Small Cap Value Fund sold 10200.0 shares to see its total holdings shrink to 4.8 million shares valued at over $83.6 million and representing 3.33% of the shares outstanding. Fidelity Value Fund sold -0.11 million shares to bring its total holdings to over 3.9 million shares at a value of $67.85 million. Fidelity Value Fund now owns shares totaling to 2.70% of the shares outstanding.
Shares of Constellium SE (NYSE: CSTM) opened at $20.23, down -$0.16 from a prior closing price of $20.39. The company’s stock has a 5-day price change of 0.91% and 9.67% over the past three months. CSTM shares are trading 68.72% year to date (YTD), with the 12-month market performance up to 72.37% higher. It has a 12-month low price of $11.61 and touched a high of $20.68 over the same period. CSTM has an average intraday trading volume of 767.60K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 6.64%, 13.60%, and 19.80% respectively.
Institutional ownership of Constellium SE (NYSE: CSTM) shares accounts for 83.36% of the company’s 144.30M shares outstanding. Mutual fund holders own 41.61%, while other institutional holders and individual stakeholders account for 42.00% and — respectively.
It has a market capitalization of $2.88B and a beta (3y monthly) value of 2.03. The stock’s trailing 12-month PE ratio is 19.26, while the earnings-per-share (ttm) stands at $1.04. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.91% over the week and 2.76% over the month.
Analysts forecast that Constellium SE (CSTM) will achieve an EPS of $0.35 for the current quarter, $0.5 for the next quarter and $2.14 for 2024. The lowest estimate earnings-per-share for the quarter is $0.23 while analysts give the company a high EPS estimate of $0.49. Comparatively, EPS for the current quarter was $0.22 a year ago. Earnings per share for the fiscal year are expected to decrease by -49.49%, and 80.32% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 5 brokerage firm advisors rate Constellium SE (CSTM) as a “Strong Buy” at a consensus score of 1.00. Specifically, 5 Wall Street analysts polled rate the stock as a buy, while 0 of the 5 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the CSTM, a number of firms have released research notes about the stock. JP Morgan stated their Overweight rating for the stock in a research note on May 08, 2023, with the firm’s price target at $24.
